Sera Prognostics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $77.9M
- Price
- $1.99
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.11%
- Volume
- 26.3K
About
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
Quick stats
Shares outstanding39.2M
Computed float42.5M
Float / shares108.6%
Cash runway (months)15.3
Key info
SectorHealthcare
IndustryMedical - Diagnostics & Research
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001534969
Websitehttps://www.sera.com
AI Summary
AI-generated1/19
minorbullishexecutive change
SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER
Sera Prognostics appointed Scott Gleason as Chief Financial Officer, effective August 31, 2026, bringing over 25 years of experience in healthcare diagnostics and capital markets.
Gleason succeeds Austin Aerts, who transitions to an advisory role after serving as CFO since June 2023 and guiding the company through its IPO.
CEO Zhenya Lindgardt emphasized that Gleason's financial leadership and investor relations expertise will be critical as the company expands access to its PreTRM Test and strengthens commercial execution.